% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Palleis:155385,
      author       = {Palleis, Carla and Brendel, Matthias and Finze, Anika and
                      Weidinger, Endy and Bötzel, Kai and Danek, Adrian and
                      Beyer, Leonie and Nitschmann, Alexander and Kern, Maike and
                      Biechele, Gloria and Rauchmann, Boris Stephan and Häckert,
                      Jan and Höllerhage, Matthias and Stephens, Andrew W and
                      Drzezga, Alexander and Eimeren, Thilo and Villemagne, Victor
                      L and Schildan, Andreas and Barthel, Henryk and Patt,
                      Marianne and Sabri, Osama and Bartenstein, Peter and
                      Perneczky, Robert and Haass, Christian and Levin, Johannes
                      and Höglinger, Günter},
      collaboration = {Tauopathies, German Imaging Initiative for},
      title        = {{C}ortical [18 {F}]{PI}-2620 {B}inding {D}ifferentiates
                      {C}orticobasal {S}yndrome {S}ubtypes.},
      journal      = {Movement disorders},
      volume       = {36},
      number       = {9},
      issn         = {1531-8257},
      address      = {New York, NY},
      publisher    = {Wiley},
      reportid     = {DZNE-2021-00625},
      pages        = {2104 - 2115},
      year         = {2021},
      abstract     = {Corticobasal syndrome is associated with cerebral protein
                      aggregates composed of 4-repeat $(~50\%$ of cases) or mixed
                      3-repeat/4-repeat tau isoforms $(~25\%$ of cases) or
                      nontauopathies $(~25\%$ of cases).The aim of this
                      single-center study was to investigate the diagnostic value
                      of the tau PET-ligand [18 F]PI-2620 in patients with
                      corticobasal syndrome.Forty-five patients (71.5 ± 7.6
                      years) with corticobasal syndrome and 14 age-matched healthy
                      controls underwent [18 F]PI-2620-PET. Beta-amyloid status
                      was determined by cerebral β-amyloid PET and/or CSF
                      analysis. Subcortical and cortical [18 F]PI-2620 binding was
                      quantitatively and visually compared between
                      β-amyloid-positive and -negative patients and controls.
                      Regional [18 F]PI-2620 binding was correlated with clinical
                      and demographic data.Twenty-four percent (11 of 45) were
                      β-amyloid-positive. Significantly elevated [18 F]PI-2620
                      distribution volume ratios were observed in both
                      β-amyloid-positive and β-amyloid-negative patients versus
                      controls in the dorsolateral prefrontal cortex and basal
                      ganglia. Cortical [18 F]PI-2620 PET positivity was
                      distinctly higher in β-amyloid-positive compared with
                      β-amyloid-negative patients with pronounced involvement of
                      the dorsolateral prefrontal cortex. Semiquantitative
                      analysis of [18 F]PI-2620 PET revealed a sensitivity of
                      $91\%$ for β-amyloid-positive and of $65\%$ for
                      β-amyloid-negative cases, which is in excellent agreement
                      with prior clinicopathological data. Regardless of
                      β-amyloid status, hemispheric lateralization of [18
                      F]PI-2620 signal reflected contralateral predominance of
                      clinical disease severity.Our data indicate a value of [18
                      F]PI-2620 for evaluating corticobasal syndrome, providing
                      quantitatively and regionally distinct signals in
                      β-amyloid-positive as well as β-amyloid-negative
                      corticobasal syndrome. In corticobasal syndrome, [18
                      F]PI-2620 may potentially serve for a differential diagnosis
                      and for monitoring disease progression. © 2021 The Authors.
                      Movement Disorders published by Wiley Periodicals LLC on
                      behalf of International Parkinson and Movement Disorder
                      Society.},
      keywords     = {Alzheimer Disease: diagnostic imaging / Amyloid
                      beta-Peptides / Diagnosis, Differential / Humans /
                      Positron-Emission Tomography / Syndrome / Alzheimer's
                      disease (Other) / PET (Other) / corticobasal syndrome
                      (Other) / four-repeat tauopathies (Other) / tau (Other)},
      cin          = {AG Levin / AG Höglinger 1 / Clinical Research (Munich) /
                      AG Boecker / AG Düzel / AG Haass},
      ddc          = {610},
      cid          = {I:(DE-2719)1111016 / I:(DE-2719)1110002 /
                      I:(DE-2719)1111015 / I:(DE-2719)1011202 / I:(DE-2719)5000006
                      / I:(DE-2719)1110007},
      pnm          = {353 - Clinical and Health Care Research (POF4-353) / 352 -
                      Disease Mechanisms (POF4-352)},
      pid          = {G:(DE-HGF)POF4-353 / G:(DE-HGF)POF4-352},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:33951244},
      doi          = {10.1002/mds.28624},
      url          = {https://pub.dzne.de/record/155385},
}